Assertio (NASDAQ:ASRT) Now Covered by Analysts at HC Wainwright

HC Wainwright started coverage on shares of Assertio (NASDAQ:ASRT) in a report issued on Wednesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $4.00 price objective on the stock.

A number of other brokerages have also recently commented on ASRT. StockNews.com cut shares of Assertio from a buy rating to a hold rating in a research note on Wednesday, May 15th. Alliance Global Partners began coverage on shares of Assertio in a research note on Tuesday, May 28th. They set a buy rating and a $2.75 price objective for the company. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of $4.44.

Assertio Trading Up 18.3 %

Shares of Assertio stock opened at $1.36 on Wednesday. The company has a 50-day moving average of $1.05 and a two-hundred day moving average of $0.97. Assertio has a 12-month low of $0.73 and a 12-month high of $5.78. The company has a current ratio of 1.87, a quick ratio of 1.45 and a debt-to-equity ratio of 0.29. The stock has a market cap of $129.36 million, a PE ratio of -0.34 and a beta of 0.90.

Assertio (NASDAQ:ASRT) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.04. The firm had revenue of $32.45 million during the quarter, compared to analysts’ expectations of $28.93 million. Assertio had a positive return on equity of 10.80% and a negative net margin of 234.40%. On average, research analysts anticipate that Assertio will post -0.13 EPS for the current fiscal year.

Institutional Trading of Assertio

A number of hedge funds have recently bought and sold shares of ASRT. SG Americas Securities LLC lifted its stake in shares of Assertio by 45.4% during the 4th quarter. SG Americas Securities LLC now owns 55,769 shares of the company’s stock worth $60,000 after purchasing an additional 17,417 shares during the period. Alps Advisors Inc. grew its holdings in Assertio by 99.9% in the 3rd quarter. Alps Advisors Inc. now owns 110,594 shares of the company’s stock valued at $283,000 after buying an additional 55,259 shares during the period. Alethea Capital Management LLC purchased a new stake in Assertio in the 3rd quarter valued at about $343,000. Denali Advisors LLC increased its stake in shares of Assertio by 286.9% during the 1st quarter. Denali Advisors LLC now owns 165,200 shares of the company’s stock valued at $158,000 after acquiring an additional 122,500 shares during the last quarter. Finally, TSP Capital Management Group LLC lifted its holdings in shares of Assertio by 14.7% during the 4th quarter. TSP Capital Management Group LLC now owns 180,950 shares of the company’s stock worth $194,000 after acquiring an additional 23,150 shares during the period. Institutional investors and hedge funds own 48.96% of the company’s stock.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.